Thank you operator, welcome to Medivir's Q2 Webcast. Please move to slide number two. Today's presentation will be held by myself, Magnus Christensen, Interim Chief Executive Officer and Chief Financial Officer of Medivir, Fredrik Öberg, our Chief Scientific Officer. I am the Interim Chief Executive Officer during the recruitment process of the new Chief Executive Officer coming into the company. Next slide, please. I will not go through this, recommend you to read it at our homepage, where you can find the presentation as well. Please move to slide number 5. Here is today's agenda. I will start off with an overview of Medivir, take you through the financial highlights for quarter two, talk about the remetinostat revenue share agreement that we announced beginning of this week. I will hand over to Fredrik, who will present MIV-818 in more detail and most importantly, our planned combination study. Fredrik Öberg will continue to present our other assets as well before we open up for a Q&A session. Next slide, please. Medivir was founded in 1988 and listed on Nasdaq Stockholm since 1996. With the financial injection in Q1, we believe we have a strong cash balance, and in the end of Q2, we reported a cash balance of SEK 248 million. According to our current plans, the cash run rate is well into the year 2023. End of Q2, we were 8 FTEs, and as we announced in beginning July, Malene Jensen will join Medivir as Vice President of Clinical Development and foremost for our project MIV-818. We are really looking forward to that and she will start in the beginning of September. As you probably know, we focus both financially and personnel on our wholly-owned asset, MIV-818, which is a liver-directed nucleotide prodrug. MIV-818 has received orphan drug designation both in the EU and the U.S., and we're currently in phase I-B clinical development and plan to start our combination trial later this year, which Fredrik will talk more about later in the presentation. The data from the phase I-B study monotherapy will be presented at ESMO in the middle of September. I would also like to highlight that we're outlicensing birinapant to IGM Biosciences in beginning of this year. Next slide, please. Here is an overview of our clinical projects. We have a focused clinical program, MIV-818, targeting liver cancer, and it's currently in phase I, and we're looking forward to start a combination trial later this year. We also have a partner asset, birinapant, which will enter phase I clinical development by IGM later this year, according to IGM's Q2 report. Of course, we're very excited to follow that study. To remind you that when IGM start the combination study, we will receive $1.5 million. We also do have two other clinical exciting programs for partnering and outlicensing, remetinostat and MIV-711, which Fredrik will present more later on. Please see slide number nine. Here you can see the financial summary for quarter two. All numbers are in million SEK. The turnover for quarter two amounts to SEK 1 million, which is lower compared to last year and relates to royalty income from Xerclear. Accumulated for this year, the turnover amounts to around SEK 11, which is more or less the same level as last year. Other external expenses are higher than last year and relates mainly to higher costs for clinical studies and mainly preparation for the upcoming combination study. Personnel costs are lower and relates to fewer FTE compared to last year. As you can see, the loss for quarter two is around SEK 17 million compared to minus SEK 13 million last year. The cash flow from operating activities in Q2 is around SEK 22 million minus, compared to minus SEK 23 million last year. As I mentioned, the cash position at the end of Q2 is SEK 248 million, and that's more than enough to complete ongoing clinical activities. According to current plans, we're in cash well into the year 2023. Please move to slide number 11. Early this week, we announced that we signed the revenue share agreement for remetinostat. As a reminder, Medivir acquired remetinostat from Celldex in 2016. In total, there's more than three stakeholders in the agreement, including Medivir. The original arrangement between Medivir and the stakeholders include a milestone payment as well as royalty obligation to the stakeholders when Medivir develops markets or outlicense remetinostat. It's positive now is that the original agreement has been renegotiated so that the compensation that we're obliged to pay in potential future outlicensing of remetinostat is based only on the distribution of actual future revenues to Medivir. We believe that with this revenue share agreement in place, we have created significantly improved condition for potential out-licensing or sale for remetinostat. With this, I will hand over to Fredrik Öberg that will present more details about MIV-818. Thank you. If I could have slide number 13. We're advancing our lead asset, MIV-818, for the treatment of hepatocellular carcinoma. This HCC is the major type of primary liver cancer, which constitutes a large unmet medical need. The market for HCC is projected to grow rapidly, and there are two reasons underlying this. We see that liver cancer incidence and mortality are increasing, partly due to an increase in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The major driver of market growth in the coming years is the introduction of new combination therapies. We're expecting the market to grow from around SEK 1 billion 2020 to around $5 billion 2029. If I could have the next slide, number 14, please. Our initial focus for MIV-818 is the advanced stage HCC population. We'll see that highlighted in this treatment schedule coming up. For this two systemic therapies, two main classes of drugs are used as standard therapy here. The tyrosine kinase inhibitors, for a long time only represented by sorafenib, followed by regorafenib, lenvatinib, cabozantinib, and more in this class of tyrosine kinase inhibitors. The other major class entering more lately is checkpoint inhibitors, with pembrolizumab which has accelerated approval in the U.S. However, recently, good data from combinations, especially the atezolizumab bevacizumab in first line HCC has provided good data, rapidly changing the treatment landscape. We see a strong trend towards combination therapies in this space. We know that additional checkpoint inhibitor combinations with tyrosine kinase inhibitors, for example pembrolizumab and lenvatinib and others, are in late-stage clinical development, and will probably move into this space as well. We would think that we need to be in this space, in combinations to be competitive. If we move to the next slide, number 15, please. A few words about MIV-818. It's an orally administered prodrug. It's designed to be rapidly metabolized in the liver, thereby targeting the active metabolites in the liver, giving high exposure in the liver and limiting systemic exposure and toxicities. This is a unique mechanism of action in this liver cancer space, which makes it attractive to be combined with many targeted and non-targeted drugs that are used in this space. The two major classes also have both preclinical data and scientific rationale to be combined. The tyrosine kinase inhibitors, among other things, induce angiogenesis inhibition, which in turn induces hypoxia in the tumor, and hypoxia increases the expression of certain enzymes that metabolize MIV-818 to the active metabolites, increasing the levels of active metabolites in the tumor. In terms of checkpoint inhibitors, they rely on an immune response, and MIV-818 is incorporated into DNA, inducing DNA damage, and thereby also increasing the immunogenicity of the tumor. Potentially these two mechanisms are interesting to combine with MIV-818. If we move to slide 16. There's an overview of the clinical development of MIV-818. We have now completed the phase I-B monotherapy part, and are advancing into combination studies. There are several differences in the patient population, for instance, that we're going to treat here. This combination study will include patients with hepatocellular carcinoma who have progressed on or are intolerant of first-line therapy, whereas the monotherapy with our main objective of safety and tolerability included patients both with metastatic liver disease, intrahepatic cholangiocarcinoma, and HCC. These were late-stage patients with sometimes excessive extrahepatic disease. Now we're focusing in on HCC with healthier patients and also in combinations. The first part will be a dose escalation part, either MIV-818 in combination with nivolumab or MIV-818 in combination with pembrolizumab. A standard 3+3 design designed to identify a recommended phase II dose for the combinations. Moving into an expansion phase with the possibility then to look more closely at efficacy signals and generate more safety data. The selection, as I said, was based on the relation of the scientific rationale, preclinical data, the safety profiles of these other drugs. We also think strategically that this makes sense, as these are the 2 main classes of drugs used in advanced HCC. If we move to the next slide number 17. In summary, we continue to advance MIV-818 and the clinical development program. We have completed the phase I-B monotherapy, which enrolled the late-stage patients, and now we're moving into earlier treatment lines, healthier patients with the combinations. The phase I-B monotherapy data, as Magnus mentioned, will be presented at the ESMO Congress mid-September. The combination study will be the two parallel streams will be done with the combinations. We're looking at focusing this on HCC patients who have progressed on or are intolerant of first-line therapy. We're on track of starting enrollment of patients for the combination study later this year. We plan to conduct this study both in Europe and in Asia. Let me say a few words about other assets. Moving to slide 19. We currently have two clinical programs that we're looking to partner or out-license. remetinostat, which is a topical HDAC inhibitor, has completed three phase II studies. The first one in cutaneous T-cell lymphoma, which showed an objective response rate of 40%, but importantly, reduced pruritus itching in 80% of the patients. This is an aspect of the disease that is important to treat. Also, two investigator-sponsored studies have been performed, one in basal cell carcinoma. The data from this study was published recently in Clinical Cancer Research. The overall response rate was 70%. It recruited several histological subtypes of basal cell carcinoma. Lastly, the squamous cell carcinoma study that was also performed by the Stanford group included some different histological subtypes as well of squamous cell carcinoma, where we had a really good response, although the patient numbers were low. Nevertheless, we're very excited about the data around remetinostat because we believe now that we have a phase III-ready asset which has shown positive results and is effective across many different subtypes of skin cancers. Lastly, we also have MIV-711, for which Medivir has conducted a phase II study demonstrating positive effects on bone and cartilage, disease-modifying effects in joints in the knee after a quite short study of six months treatment with MIV-711. We're excited about having these two assets, although the osteoarthritis area is outside of Medivir's core focus at the moment, which is oncology. I'll hand over to Magnus. Thank you, Fredrik. Please move to slide number 20. Here we have highlighted the known upcoming milestones for the remaining part of this year. Firstly, as we mentioned, the data from the phase I-B monotherapy we presented at ESMO Congress in September. Secondly, we're looking forward to starting the combination study with MIV-818 later this year. As well, IGM has announced in the Q2 report that they plan to start their combination study with birinapant and IGM-8444 later this year as well. When they start, we receive a milestone payment of $1.5 million. With that, next slide please, I hand over to the operator. I'll open up for a Q&A session. Thank you. If you would like to ask a question, please press zero one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero two to cancel. There will be a brief pause while questions are being registered. The first question comes from the line of Emanuela Branchetti from H.C. Wainwright. Please go ahead. Your line is open. Good afternoon, guys, and thank you for taking my questions. A couple for me. Regarding the ESMO presentation on MIV-818 data, could you help us setting the expectations for the data? Will the data be focused on safety? Will full data be presented, including maybe biomarkers data from the study? I can answer that. The main focus and the primary objective of the phase I-B monotherapy was safety and tolerability. Of course that will be an important part of that presentation. There will also be, of course, some of the exploratory objectives like biomarkers presented. Got it. Thank you for that. With the Phase I/II-A starting in Europe, you mentioned in your prepared remarks, Magnus, you're planning to expand the development with studies in Asia. A conversation with a partner already started, and when should we expect an update on that? Partner for MIV-818, is that what's your question? Yes. Okay. Thank you for the question. As we have said before, we're really looking forward to starting the combination study there. I think the best for Medivir today is really to gather all the data from the combination study and from the expansion phase. I think the data will tell us what the next step is for Asia and the remaining part of the world as well. I think we will see the data first before we take a strategic decision on that. Got it. Thank you for that. Also regarding the remetinostat, could you provide more color on the expected regulatory path for that? Will this require a single phase III study? If this is the case, how many patients and how long would that study require since I think one of the objective would be to test durability of the effect. It's difficult to say in general terms because it will be different depending on which indication you would prioritize. The competition is different and the possibilities of doing a placebo-controlled study is also different. I couldn't really detail that for you. We believe that the fact that there are three indications that are potentially interesting for remetinostat opens up several possibilities for different partners who are interested in different areas to continue to develop and move into a phase III study. Got it. Thank you very much. Thank you. Thank you. The next question comes from Jacob Mekhael from Kempen. Please go ahead, your line is open. Okay. Hi there, and thanks for taking my question. I have a few questions here for Ingrid, who is the Analyst on this stock. I have a few questions on the MIV-818, the upcoming trial. Maybe I missed it, can you please just clarify what will be the specific line of treatment that you will focus on? Do you have an estimate of what is the% of the total HCC patients that will move to this line? The target population are patients who are either intolerant or have failed first-line treatment. With the advent of the new combinations, this is a sort of uncharted territory because we don't really know how large that population is. We expect that that population will grow. Second line will grow but it's also a way into that space. I guess that the data from that study will tell us if we are continuing in second line or trying to move in either direction. I guess that your question is well taken because it will be very interesting to see how that first line develops. We now have the combination of atezolizumab and bevacizumab, but there are other contenders there as well. Okay, thank you. Do you plan on moving both combination arms into the phase II portion of the trial? Are you just going to select one of them? If you do, is there going to be a safety and efficacy benchmark that you'd be looking at? At this point, we don't know. We have contingency plans to go forward with one of the 2 combinations or both, depending on the data we see in the dose escalation part. It's a possibility, of course, to do the expansion in 1 if that seems more favorable. The second part of your question was? I didn't catch that. It was if you have any safety and efficacy benchmarks that you'd be looking for. Both lenvatinib and pembrolizumab do have toxicities. We believe that the toxicities with MIV-818 are not going to be synergistic in any way, but different. That remains to be seen. We don't want to add tolerability burden in the combination, of course. Okay. That's good. Do you have any idea on which combination might work better? Do you have any rationale or some indication at the moment? At the moment, this is something, of course, we're thinking about, but at the moment, we have nothing really to guide us in what patient population would benefit more or have a better response rate. I think that's too early to say. Okay, thank you. I just have one more question, and then I'll be done. I'm trying to say it. Is it birinapant? Are you able to comment on what would be the potential milestones beyond the $1.5 million expected around the end of the year? For this year, I think it's, as we said, that the complete package of milestones is $350 million. I think we announced that earlier this year, and it's based on phase milestones, regulatory and development milestones. On top of that, we have royalties. What we expect this year is the starting of their combination trial with their antibody 8444 with birinapant. That's what we expect this year. As IGM is in charge of the development plans for birinapant, it's really they are in charge of the clinical studies from now as we outlined it, and they have the global rights for birinapant. Okay, well, that's great. Thank you very much for answering my questions. Thank you. Thank you. We have a question from Niklas Elmhammer from Redeye. Yeah, hello. Thank you, and good afternoon. I hope I'm not being impolite, but maybe if you can give us an update on the process for recruiting a permanent CEO. Yes, I can do that. Thank you for the question. I could say that the process is ongoing, and when we have a final candidate, we will give the notice to the market. What I can say now is the process is ongoing at the moment. Okay, thank you. Did I understand you correctly that the recommended dose for the phase II is 40 mg? I'm talking, of course, of 818. MIV-818 in monotherapy. The recommended phase II dose in the two upcoming combinations remains to be decided based on the dose escalation phase. That's correct for the monotherapy. Okay. How did you come about that? I guess you investigated some higher doses than. Yes, in the dose escalation phase, we did go higher than 40 mg. That is correct. Yeah. Okay, regarding remetinostat, I was wondering, is this project, do you believe it's partnering-ready, or do you need to take any further activities? I would say it's definitely partnering-ready. Okay. Could you tell us a little bit regarding the business case for example basal cell carcinoma, how do you see remetinostat being positioned here, for example? I don't want to preempt any interested parties, what they would be looking at. I guess that both in a neoadjuvant setting, treating before surgery, reducing the size, or in patients where it's difficult to do surgery or have had a lot of surgeries and are tired of having a lot of surgery. There are areas in both BCC and squamous cell carcinoma where that could be a possibility. Of course, there are differences in the histological subtypes of BCC. Superficial BCC, for instance, as is detailed in this Clinical Cancer Research article there the response rate is I think 100%. There you could possibly replace surgery. Okay. Thank you. That's very helpful. I have no other questions. Thank you. Thank you, Niklas. Thank you. We have no further questions. I will pass back for any closing comments. Thank you, operator. Thank you all for participating in this webcast for Medivir Q2 report. I can just sum up with that we are really looking forward to start the combination study with MIV-818 later this year. Thank you and have a nice day. Thank you for attending. You may now disconnect your lines.